Navigation Links
New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
Date:6/11/2009

<24 months; and 3) a single dose of Prevenar 13 at age 24 to <72 months. Each of the 3 regimens was shown to elicit immune response levels against all 13 serotypes that were either comparable to or greater than the IgG antibody concentrations achieved in infants after a 3-dose infant series and to have acceptable tolerability and safety profiles.

Overall, the most frequently reported adverse events in the Phase 3 trials included injection site reactions, (redness, swelling, and tenderness), fever (greater than or equal to 38 degrees C/100.4 degrees F), irritability, drowsiness, restless sleep, decreased appetite, vomiting, diarrhea and rash.

Health Economic Models

Three health economic models presented at ESPID estimated the potential public health and economic impact of Prevenar 13. The results of the analyses in the Netherlands, the UK, and Germany and the US suggested that the introduction of Prevenar 13, if approved, to national immunization programs has the potential to further reduce PD levels in children who are vaccinated as well as in the unvaccinated population (through a herd effect). Based on these economic models, the researchers estimated that routine vaccination with Prevenar 13 could be cost effective or cost saving.

Registration Status

To date, Wyeth has submitted regulatory applications for the pediatric use of Prevenar 13 in more than 45 countries. In December 2008, Wyeth submitted a marketing authorization application (MAA) for Prevenar 13 to the European Medicines Agency (EMEA). In March 2009, Wyeth submitted a Biologic License Application (BLA) for Prevenar 13 to the U.S. Food and Drug Administration (FDA). Last month, the FDA granted the BLA priority review -- a designation given to products that, if approved, would be a significant therapeutic or public health advance. Prevenar 13 is also being studied in
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... http://photos.prnewswire.com/prnh/20130307/600769 ... (either DNA or RNA) into cells. This technology helps ... cells and protein metabolism by affecting the nuclear genes. ...
(Date:7/11/2014)... AZ (PRWEB) July 11, 2014 ... device company specializing in the soft tissue reconstruction ... All-Suture Anchor System for surgeries involving the shoulder ... fixation through a novel, inserter-controlled deployment method. The ... to partial deployment, anchor pull-out, or anchor displacement ...
(Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
(Date:7/10/2014)... Senior supply chain management executives from over 50 ... of “Reducing Cost, Lead Time, & Defects in the ... the partnership of the Bio Supply Management Alliance ( ... SCMI) of the University of San Diego in ... Institute of Peace and Justice in San Diego, Devendra ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... few as 1 cell , Karen Dolter ... RNA microprep kit provides a,convenient method for isolating total ... is bound to a solid support, which eliminates the,need ... high quality, with no detectable DNA contamination and is ...
... higher transformation efficiency of ligated DNA , ... ,Stratagene Cloning Systems, Inc. , Stratagenes new, high-efficiency ... efficiency of ligated DNA. Epicurian,Coli ... for ligated DNA that were up to 25-fold ...
... Mycoplasma PCR Primer Set for fast and easy ... Arrington ,Yale University , D. R. Staggs ,Genetic Applications ... mammalian cell cultures can substantially,reduce the potency of transfection ... before the optimal amounts of LipoTAXI ...
Cached Biology Technology:Fast Isolation of Total RNA from Small Numbers of Cells 2Fast Isolation of Total RNA from Small Numbers of Cells 3Fast Isolation of Total RNA from Small Numbers of Cells 4Fast Isolation of Total RNA from Small Numbers of Cells 5Fast Isolation of Total RNA from Small Numbers of Cells 6New Competent Cells for Highest Transformation Efficiencies 2New Competent Cells for Highest Transformation Efficiencies 3New Competent Cells for Highest Transformation Efficiencies 4New Competent Cells for Highest Transformation Efficiencies 5New Competent Cells for Highest Transformation Efficiencies 6New Competent Cells for Highest Transformation Efficiencies 7New Competent Cells for Highest Transformation Efficiencies 8Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection,of Mammalian Cells 2Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection,of Mammalian Cells 3
(Date:7/11/2014)... "mouse TRAP" to capture the early signs of kidney ... the Journal of Clinical Investigation . Their new ... extract cellular and genetic information from a variety of ... Institute for Medical Research in 2008, TRAP involves attaching ... of the cell type of interest. Scientists can then ...
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
(Date:7/11/2014)... division of the striatum is also involved in ... of substance P in the striatal marginal division ... his team, College of Biophotonics, South China Normal ... P receptor, neurokinin 1 was highly expressed in ... rats. Unilateral or bilateral injection of an antisense ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... disease that can lead to life-threatening heart and digestive ... thought, according to research from The University of Texas ... years now, and this year the number of disease-causing ... integrative biology and philosophy at The University of Texas ...
... the most stressful thing that can happen to anybody. But ... of traumatic experiences. Most humans come to terms with it ... How weaning takes place, however, can have a dramatic effect on ... this is so, at least for horses, comes from the latest ...
... Over the next decade, the population of cancer survivors over ... "We can expect a dramatic increase in the ... a history of cancer," said Julia Rowland, Ph.D., director of ... Control and Population Sciences at the National Cancer Institute (NCI). ...
Cached Biology News:Chagas disease may be a threat in South Texas, says researcher 2The short goodbye: Weaning foals 2The short goodbye: Weaning foals 3Older cancer survivor population to increase substantially 2
... receptors constitute the principal excitatory ... classes of glutamate receptors exist: ... Ionotropic glutamate receptors are oligomeric ... NMDA1-3, KAI-2) which comprise ligand-gated ...
... Block Moto Alpha unit with motorized heated lid ... that is useful for microarrays and chips. The ... blocks. The sealing force of the motorized lid ... to give repeatable results. This interchangeable Moto Alpha ...
Caspr2 Antigen: Fusion protein amino acids 96-1265 (extracellular domain) of human Caspr2 Accession Number: NP_054860...
... N,N- bis- (3-D-Gluconamidopropyl)deoxycholamide ... of CHAPS and CHAPSO. Has reduced electrostatic ... exchange chromatography on DEAE-cellulose. Aggregation number: 8-16. ... in H 2 O. Aggregation number 8 ...
Biology Products: